Wegovy for MASH Liver Disease Treatment
.
Wegovy approved for a New use: Treating Advanced Liver Disease
by Dr.Jennifer Chen, Pulitzer-winning Chief Editor
In a critically important development for patients with advanced liver disease, the U.S. Food and Drug Governance (FDA) has approved Wegovy (semaglutide) for the treatment of adults with metabolic dysfunction-associated steatotic liver disease (MASLD), specifically those with extensive fibrosis, or scarring, in the liver. This expands Wegovy’s existing approvals for obesity treatment and preventing heart attacks and strokes in high-risk individuals.
“This is a very exciting development for people who are experiencing MASH,” says Dr. Ani Amirian-Kardashian, an assistant professor and hepatologist with Keck Medicine at the university of Southern California in Los Angeles. “Prior to Wegovy,there was only one other FDA-approved medication for MASH – a limited treatment option. The mainstay of treatment for MASH has been dietary and lifestyle modification to achieve adequate weight loss to reverse fat buildup and inflammation in the liver.”
Understanding MASLD and MASH
MASLD, formerly known as nonalcoholic fatty liver disease, develops when fat accumulates in the liver, leading to inflammation and tissue damage. Over time, this can progress to scarring (fibrosis) and ultimately cirrhosis, possibly requiring a liver transplant. Metabolic-associated steatohepatitis (MASH) is a severe form of MASLD characterized by significant inflammation and scarring. Conditions like obesity, type 2 diabetes, and high cholesterol increase the risk of developing MASH.
How Wegovy Works in MASH
The FDA’s approval is based on clinical trial data demonstrating that Wegovy can reduce liver scarring and improve overall liver health in patients with MASH. The trial showed that after 72 weeks, a considerably higher percentage of patients treated with wegovy experienced improvement in liver scarring and no worsening of MASH, compared to those receiving a placebo.
What are the Side Effects?
As with any medication, Wegovy can cause side effects.Common side effects reported in clinical trials include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, and dizziness.
Expanding Access to Treatment
This new approval is expected to make treatment more accessible for individuals with MASH. “Having this additional indication will hopefully allow more patients who need this medication to get it, with insurance coverage,” says Dr. Amirian-Kardashian.
The FDA will continue to monitor Wegovy’s long-term effects through ongoing trials,aiming to determine if the initial improvements in inflammation and scarring translate into fewer deaths,liver transplants,or other liver-related health issues. This approval represents a significant step forward in the treatment of a growing public health concern.